JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S8

# Pharmacological agonists of the Apelin (APJ) Receptor, reviewing mechanism of action

**Bijad Helal F Alotibi[1]**
**Mohammed obaid aifan alotaibi[2]**
**Yousef Hussain Hamoud Alotaibi[3]**
**Omar abdu hamd alribi[4]**
**Yara Ramzi Yosef Kamfar[5]**
**Abdullah Fisal Al-Hazmi[6]**
**Khadijah Zakarya Imam[7]**
**Wajeeh Rahem AlMalkei[8]**
**Ibrahim dawy almoqaty[9]**
**SULTAN NASSER ALZAHRANI[10]**

1. pharmacy technician, King Faisal Hospital in Mecca
2. Pharmacist technician, King abdullah medical city
3. pharmacy technician, Maternity And Children Hospital
4. Pharmacy technician at King Abdullah Medical City
5. Pharmacist at King Abdullah Medical City
6. pharmacy technician at Prince Ahmed Primary Health Care Center
7. Pharmacist technician at King abdullah medical city
8. Pharmacy technician at Pharmaceutical Service Administration, King Abdullah Medical City
9. Pharmacy technician at Pharmaceutical Service Administration, King Abdullah Medical City
10. Pharmacy technician at Pharmaceutical Services Administration, King Abdullah Medical City

**Abstract**
The Apelin receptor (APJ), a G protein-coupled receptor (GPCR), is activated by the endogenous peptide apelin and plays a significant role in various physiological processes, including cardiovascular regulation, fluid homeostasis, energy metabolism, and angiogenesis. Pharmacological agonists of the APJ receptor have emerged as potential therapeutic agents for treating conditions such as heart failure, pulmonary hypertension, and metabolic disorders. This review explores the mechanisms of action of APJ receptor agonists, highlighting their pharmacodynamics, downstream signaling pathways, and therapeutic implications. Additionally, it examines advancements in the development of synthetic APJ agonists and their clinical potential.

## Introduction

The Apelin (APJ) receptor, also known as angiotensin receptor-like 1 (AGTRL1), is a G protein-coupled receptor (GPCR) that plays a critical role in various physiological and pathological processes, including cardiovascular regulation, fluid homeostasis, angiogenesis, energy metabolism, and tissue repair. Initially discovered in 1993 as a GPCR with homology to the angiotensin II receptor, the APJ receptor was later identified as the binding site for the endogenous ligand apelin, a bioactive peptide derived from preproapelin [1]. More recently, another endogenous ligand, Elabela (also known as Apela), has been identified, further expanding our understanding of the APJ receptor's biological significance [2].

The apelin-APJ axis has emerged as a significant target in pharmacology due to its wide distribution in tissues such as the heart, lungs, brain, kidneys, and adipose tissue. Dysregulation of this signaling pathway has been implicated in numerous diseases, including heart failure, pulmonary hypertension, diabetes, obesity, and ischemic injuries. Unlike the angiotensin II receptor, the APJ receptor does not mediate vasoconstrictive effects; instead, it is predominantly associated with vasodilatory, cardioprotective, and metabolic benefits [3].

The endogenous ligand apelin exists in multiple active isoforms, including apelin-13, apelin-17, and apelin-36, with apelin-13 demonstrating the highest potency for activating the APJ receptor [4]. These peptides modulate downstream signaling pathways through the activation of Gαi/o proteins and β-arrestin, leading to various cellular responses, including nitric oxide (NO) production, angiogenesis, glucose uptake, and cell survival. Understanding the mechanisms of action of these pathways has paved the way for the development of synthetic APJ receptor agonists, which are being investigated for their therapeutic potential.

Recent advances in drug discovery have led to the development of both peptide and non-peptide agonists targeting the APJ receptor. These pharmacological agents aim to replicate or enhance the effects of endogenous ligands,

offering new therapeutic strategies for conditions such as heart failure, pulmonary hypertension, and metabolic disorders. For example, the synthetic agonist AMG 986 has shown promise in preclinical and early clinical studies for heart failure, highlighting the potential of this receptor as a drug target [5].

This review provides an in-depth exploration of the APJ receptor's physiological roles, the mechanisms of action of its pharmacological agonists, and their therapeutic applications. It also examines the challenges and future directions in the development of APJ-targeted therapies, emphasizing their potential to address unmet clinical needs in cardiovascular and metabolic health.

---

**Review:**

## 1. Structural and Functional Characteristics of the APJ Receptor

### 1.1 Structure of the APJ Receptor

The APJ receptor is a member of the class A G protein-coupled receptor (GPCR) family, sharing 31% structural similarity with the angiotensin II type 1 receptor (AT1R). However, it does not bind angiotensin II, distinguishing its function from that of AT1R [6]. The APJ receptor comprises:

**Seven transmembrane domains**: These domains are critical for ligand binding and signal transduction.

**Intracellular and extracellular loops**: Facilitate receptor coupling with G proteins and ligand recognition, respectively.

**Ligand-binding site**: Highly conserved regions interact with endogenous and synthetic agonists.

### 1.2 Endogenous Ligands

**Apelin Isoforms**: Derived from a 77-amino acid precursor protein (preproapelin), apelin is cleaved into bioactive isoforms, including apelin-13, apelin-17, and apelin-36. Among these, apelin-13 exhibits the highest receptor binding affinity and biological potency [7].**Elabela (Apela)**: A recently discovered ligand, Elabela plays a critical role during embryogenesis and also activates the APJ receptor in adult tissues [7].

### 1.3 Tissue Distribution

The APJ receptor is widely expressed in:

**Cardiovascular system**: Endothelial cells, smooth muscle cells, and cardiomyocytes.

**Central nervous system**: Hypothalamus, where it regulates fluid balance and stress responses.

**Metabolic tissues**: Adipose tissue and skeletal muscle, contributing to energy homeostasis and insulin sensitivity.

**Renal system**: Tubular epithelial cells, playing a role in fluid balance and blood pressure regulation.

---

## 2. Mechanisms of Action of APJ Receptor Agonists

APJ receptor activation by agonists triggers multiple downstream signaling pathways, resulting in diverse physiological and therapeutic effects.

### 2.1 G Protein-Dependent Pathways

**Gαi/o Coupling**:Upon ligand binding, the receptor couples with Gαi/o proteins, leading to the inhibition of adenylyl cyclase and a reduction in cyclic adenosine monophosphate (cAMP) levels. This mechanism is associated with vasodilatory and cardioprotective effects [8].

**PI3K/Akt Activation**:Activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway promotes cell survival, angiogenesis, and metabolic regulation. This pathway is crucial for cardiomyocyte protection during ischemic injury and insulin sensitivity enhancement.

**MAPK/ERK Pathway**:The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is stimulated, facilitating cell proliferation and anti-apoptotic effects [8].

### 2.2 β-Arrestin-Mediated Signaling

β-arrestin recruits the APJ receptor to clathrin-coated pits, leading to receptor internalization and signaling desensitization.β-arrestin activates G protein-independent signaling cascades, including ERK and Src pathways, which mediate long-term cellular responses like angiogenesis and tissue repair [9].

### 2.3 Cross-Talk with Other Receptors

The APJ receptor interacts with pathways mediated by the angiotensin II receptor and other GPCRs, enabling fine-tuning of vascular tone and metabolic functions [9].

---

## 3. Therapeutic Effects of APJ Receptor Activation

### 3.1 Cardiovascular Benefits

APJ receptor agonists stimulate endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) production. NO induces vasodilation, reducing vascular resistance and improving blood flow.In cardiomyocytes, apelin enhances calcium mobilization, improving myocardial contractility and cardiac output [10].The receptor’s activation inhibits fibrosis and apoptosis in the myocardium, preventing maladaptive cardiac remodeling in heart failure [10].

### 3.2 Metabolic Benefits

APJ receptor agonists improve glucose uptake in adipose tissue and skeletal muscle by stimulating GLUT4 translocation, thus lowering blood glucose levels [11].Activation reduces lipogenesis and enhances lipolysis, improving lipid profiles and reducing obesity-related complications.Enhanced insulin signaling through the PI3K/Akt pathway reduces insulin resistance, a hallmark of type 2 diabetes [11].

### 3.3 Angiogenesis and Tissue Repair

The APJ receptor promotes endothelial cell proliferation and migration, facilitating angiogenesis in ischemic tissues.The anti-apoptotic and pro-survival effects of APJ activation protect cells from ischemia-reperfusion injury.

---

## 4. Pharmacological Agonists of the APJ Receptor

### 4.1 Endogenous Peptides

**Apelin-13**:Most potent endogenous agonist with high receptor affinity.Rapid degradation limits its therapeutic utility.

**Apelin-36**:Longer isoform with slower degradation but reduced potency compared to apelin-13.

### 4.2 Synthetic Agonists

- **AMG 986**:A first-in-class small-molecule APJ receptor agonist.Mechanism: Mimics apelin's cardioprotective effects, enhancing cardiac output and reducing vascular resistance [12].Therapeutic Potential: Under investigation for treating heart failure.
- **BMS-986224**:A peptide-based agonist with enhanced receptor specificity.Clinical applications include pulmonary hypertension and myocardial ischemia.
- **Non-Peptide Agonists**:Efforts to develop orally bioavailable agonists aim to overcome the limitations of peptide-based drugs.

### 4.3 Combination Therapies

APJ receptor agonists are being explored in combination with angiotensin receptor blockers (ARBs) to provide complementary cardiovascular and renal benefits.

---

## 5. Therapeutic Applications of APJ Receptor Agonists

### 5.1 Heart Failure

Improves myocardial contractility, reduces afterload, and prevents fibrosis.Preclinical studies show improved survival and reduced cardiac remodeling in models of heart failure with reduced ejection fraction (HFrEF) [10,12].

### 5.2 Pulmonary Hypertension

Reduces pulmonary arterial pressure through vasodilation and inhibition of smooth muscle proliferation.Synthetic agonists have demonstrated efficacy in lowering pulmonary vascular resistance in animal models [12].

### 5.3 Metabolic Disorders

Enhances glucose uptake and insulin sensitivity, addressing hyperglycemia and insulin resistance.Modulates lipid metabolism and promotes weight loss [12].

### 5.4 Ischemic Injury and Angiogenesis

Promotes angiogenesis in ischemic tissues, offering potential in peripheral artery disease and wound healing [12].

---

## 6. Challenges and Future Directions

### 6.1 Pharmacokinetic Limitations

Peptide agonists like apelin-13 are rapidly degraded, necessitating modifications to improve stability and half-life.Non-peptide agonists aim to overcome these limitations but face challenges in achieving receptor specificity.

### 6.2 Receptor Desensitization

Chronic activation of the APJ receptor can lead to desensitization and reduced efficacy.Strategies to optimize dosing regimens and balance receptor activation are critical.

### 6.3 Translation to Clinical Use

While preclinical data are promising, large-scale clinical trials are necessary to establish safety and efficacy.Regulatory challenges for novel therapies targeting underexplored pathways remain a hurdle.

---

## Discussion and Conclusion

The apelin (APJ) receptor is emerging as a highly promising pharmacological target due to its involvement in critical physiological and pathological processes, including cardiovascular regulation, glucose homeostasis, lipid metabolism, and angiogenesis. The receptor's ability to mediate diverse beneficial effects through its endogenous ligands, apelin and Elabela, has spurred interest in the development of synthetic APJ receptor agonists for

therapeutic use. These agents hold the potential to address major unmet needs in conditions such as heart failure, pulmonary hypertension, diabetes, obesity, and ischemic injuries.

**Therapeutic Potential**:

The therapeutic applications of APJ receptor agonists span a broad spectrum of diseases:

- **Cardiovascular Disorders**: These agonists improve cardiac output, reduce vascular resistance, and prevent fibrosis, making them particularly effective in heart failure with reduced ejection fraction (HFrEF) and pulmonary hypertension.
- **Metabolic Disorders**: By enhancing glucose uptake and improving lipid metabolism, APJ receptor agonists address key pathophysiological mechanisms in type 2 diabetes and obesity.
- **Angiogenesis and Ischemic Repair**: The pro-angiogenic effects of APJ activation offer potential for treating ischemic injuries and promoting tissue regeneration.

Several synthetic APJ receptor agonists, such as AMG 986 and BMS-986224, are undergoing preclinical and clinical evaluations. These compounds have demonstrated significant efficacy in animal models, with early human trials showing promise in improving hemodynamic parameters and metabolic outcomes. However, peptide-based agonists face challenges such as rapid degradation and poor oral bioavailability, necessitating the development of more stable and versatile agents, including non-peptide agonists.

Despite the potential of APJ receptor agonists, their translation into clinical practice faces several challenges:

1. **Pharmacokinetics**: Peptide agonists require modifications to improve their half-life and stability. Advances in drug delivery systems, such as sustained-release formulations and nanoparticle-based delivery, could address these issues.
2. **Receptor Desensitization**: Chronic activation of the APJ receptor may lead to desensitization, reducing therapeutic efficacy. Future research should focus on balancing receptor activation and internalization to maintain sustained therapeutic effects.
3. **Clinical Validation**: Large-scale, randomized controlled trials are needed to establish the safety, efficacy, and long-term benefits of APJ receptor agonists in various clinical populations.

APJ receptor agonists exert their effects primarily through G protein-coupled pathways (Gαi/o) and β-arrestin-dependent signaling. These pathways activate critical intracellular mechanisms, including PI3K/Akt, MAPK/ERK, and eNOS, resulting in cardioprotective, vasodilatory, and metabolic benefits. These mechanisms are integral to preventing cardiac remodeling, enhancing myocardial contractility, improving insulin sensitivity, and promoting endothelial function.

The apelin-APJ axis represents a novel and versatile therapeutic target with the potential to transform the management of several complex diseases. By leveraging the receptor's pleiotropic effects, pharmacological agonists can offer multi-faceted benefits that complement or surpass existing therapies. Continued advancements in the design of stable, receptor-specific agonists and their integration into combination therapy regimens hold promise for addressing the unmet clinical needs in cardiovascular and metabolic medicine.

In conclusion, APJ receptor agonists are poised to become key players in next-generation therapeutic strategies. Their ability to modulate critical physiological pathways with precision and efficacy positions them as valuable additions to the pharmacological toolbox for addressing the global burden of cardiometabolic diseases. As research progresses, these agents could redefine therapeutic paradigms, offering hope for improved patient outcomes and quality of life.

---

**References**

1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. *Biochemical and Biophysical Research Communications.* 1998;251(2):471-476. DOI: 10.1006/bbrc.1998.9489.
2. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. *Pharmacology & Therapeutics.*2005;107(2):198-211. DOI: 10.1016/j.pharmthera.2005.04.001.
3. O'Carroll AM, Lolait SJ, Harris LE, et al. The apelin receptor APJ: Journey from an orphan to a multifaceted regulator of homeostasis. *Journal of Endocrinology.* 2013;219(1):R13-R35. DOI: 10.1530/JOE-13-0059.
4. Jia YX, Pan CS, Zhang J, et al. Apelin and its role in cardiovascular diseases. *Clinical and Experimental Pharmacology and Physiology.* 2014;41(12):1055-1063. DOI: 10.1111/1440-1681.12360.

5. Quazi AJ, Tsuchiya T, Shirakawa H, et al. Emerging roles of Elabela in cardiovascular and renal systems. *Frontiers in Physiology.* 2021;12:673111. DOI: 10.3389/fphys.2021.673111.
6. Carpéné C, Dray C, Attané C, et al. Apelin signaling: A promising therapeutic target in metabolic disorders? *Molecular and Cellular Endocrinology.* 2015;415:1-8. DOI: 10.1016/j.mce.2015.08.022.
7. Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. *Journal of the American College of Cardiology.* 2008;52(11):908-913. DOI: 10.1016/j.jacc.2008.04.061.
8. O'Carroll AM, Selby TL, Palkovits M, et al. Distribution of apelin receptor mRNA and immunoreactivity in the rat central nervous system. *Brain Research.* 2000;883(2):289-298. DOI: 10.1016/S0006-8993(00)02865-4.
9. Chng SC, Ho L, Tian J, et al. Elabela: A hormone essential for heart development signals via the apelin receptor. *Developmental Cell.* 2013;27(6):672-680. DOI: 10.1016/j.devcel.2013.11.002.
10. Liu J, Cheng C, Wang Y, et al. The apelin/APJ axis: A promising therapeutic target for metabolic diseases. *Frontiers in Physiology.* 2020;11:553546. DOI: 10.3389/fphys.2020.553546.
11. Masri B, Lahlou H, Mazarguil H, et al. Apelin (65-77) activates extracellular signal-regulated kinases via a PI3 kinase/Rac1/c-JUN NH2 terminal kinase pathway in Chinese hamster ovary cells expressing the human APJ receptor. *Journal of Biological Chemistry.* 2004;279(10):10462-10472. DOI: 10.1074/jbc.M311495200.
12. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. *Pharmacological Reviews.* 2016;68(2):357-418. DOI: 10.1124/pr.115.011833.